S. Arif

Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients

M. Tsao, F. Shepherd, P. Ellis, 2016, British Journal of Cancer.

A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer.

T. Stockley, E. Chen, D. Graham, 2021, Lung cancer.